Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Share Price Is Still Matching Investor Opinion Despite 26% Slump

Simply Wall StNov 6 17:49 ET

[Brokerage Focus] Dongbei Securities maintains a 'buy' rating on haohai biotec (06826), indicating that its market share is expected to increase year by year.

Kingwu Financial News | Dongbei Securities issued a research report, haohai biotec (06826) has a strong medical academic background, coupled with increasing research and development investment, steadily enhancing technological advantages, and the effectiveness of hyaluronic acid products has been continuously verified and widely recognized in the market. The first generation "Haiwei" and the second generation "Jiaolan" continue to maintain steady growth, while the third generation "Hai Mei" and "Hai Mei Yun" establish a high-end brand image. The fourth generation "Hai Mei. Yuebai" pioneered organic cross-linking of hyaluronic acid, strengthening its high-end brand position, while differentiating from the previous three generations in terms of functional features and price positioning of hyaluronic acid, meeting diversified medical and aesthetic demands. The bank stated that the company's vision

Jingu Finance NewsNov 4 01:54 ET

We Think That There Are Issues Underlying Shanghai Haohai Biological Technology's (HKG:6826) Earnings

Simply Wall StNov 1 19:33 ET

haohai biotec (06826) has not yet implemented the second phase of share buyback as of the end of October.

haohai biotec (06826) announced that, according to the Rules on Share Repurchase of Listed Companies, Shanghai Stock Exchange...

Zhitong FinanceOct 31 05:32 ET

shanghai haohai biological technology (688366.SH): has not yet implemented the second phase of share repurchase

On October 31st, Gelonhui reported that shanghai haohai biological technology (688366.SH) announced that as of October 31, 2024, the company has not yet implemented the second phase of share repurchase.

Gelonghui FinanceOct 31 04:33 ET

Haohai biotec (06826.HK) completed the cancellation of 0.8057 million H shares

On October 30th, GeLongHui announced that Haohai Biotec (06826.HK) has completed the cancellation of 805,700 H股 shares repurchased on October 30, 2024. After the cancellation, the company's total share capital has changed from 234,995,995 shares to 234,190,295 shares.

Gelonghui FinanceOct 30 08:08 ET